Fenwick Represents Nurix Therapeutics in its $250M Registered Common Stock Offering

Fenwick represented Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on targeted protein degradation medicines for oncology and autoimmune disease, in its $250 million underwritten registered offering of 24,485,799 shares of common stock at $10.21 per share.

Nurix intends to use the proceeds to advance clinical development of bexobrutideg (NX-5948) in chronic lymphocytic leukemia, explore potential autoimmune indications, expand its research and development pipeline, and for working capital and general corporate purposes. More information can be obtained from Nurix’s announcement.

The Fenwick transaction team was led by corporate partners Michael Brown and Amanda Rose, and included associates Arielle Trapp, Marianna Zabkowski, and Havyn Quigley.